
Johnson & Johnson eyes $300 stock target amid strong oncology growth and pipeline progress.
Johnson & Johnson's stock has risen 13.73% year-to-date, driven by strong oncology sales and MedTech performance. Despite a recent earnings dip due to litigation costs and biosimilar competition, the company remains optimistic about accelerated growt...


